Literature DB >> 19529920

The endocannabinoid system as a target for modelling psychosis.

Dagmar Koethe1, Carolin Hoyer, F Markus Leweke.   

Abstract

INTRODUCTION: Model psychosis is characterised by experimentally induced symptoms of withdrawal from reality, frequently accompanied by perceptual disturbances, thought disorders, delusional ideas and sometimes by hallucinations. These "altered states of consciousness" provide a long-standing and valid approach to enhance our understanding of certain aspects of schizophrenia. DISCUSSION: Targeting the endocannabinoid system to investigate its involvement in the pathophysiology of schizophrenia became increasingly relevant with the discovery of this system and amounting epidemiological evidence for a deleterious influence of cannabis use on both manifestation and course of the disease. The majority of studies in the field are targeted to investigate drug effect of cannabis and cannabinoids not immediately related to psychosis.
CONCLUSION: In this review, we summarise studies relevant for or designed as model psychosis experiments. Based on the data available, we examine the contribution of these studies to an improved neurobiological assessment of endocannabinoid functioning in psychosis and schizophrenia. An outline for future studies in the field and cross-links to other approaches to model psychosis is provided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19529920     DOI: 10.1007/s00213-009-1591-7

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  79 in total

Review 1.  Involvement of the endocannabinoid system in drug addiction.

Authors:  Rafael Maldonado; Olga Valverde; Fernando Berrendero
Journal:  Trends Neurosci       Date:  2006-02-17       Impact factor: 13.837

Review 2.  Endocannabinoid-mediated control of synaptic transmission.

Authors:  Masanobu Kano; Takako Ohno-Shosaku; Yuki Hashimotodani; Motokazu Uchigashima; Masahiko Watanabe
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

3.  Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography.

Authors:  Roy J Mathew; William H Wilson; Timothy G Turkington; Thomas C Hawk; R Edward Coleman; Timothy R DeGrado; James Provenzale
Journal:  Psychiatry Res       Date:  2002-12-30       Impact factor: 3.222

4.  Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man.

Authors:  F M Leweke; U Schneider; M Thies; T F Münte; H M Emrich
Journal:  Psychopharmacology (Berl)       Date:  1999-03       Impact factor: 4.530

5.  Effects of smoking marijuana on brain perfusion and cognition.

Authors:  Daniel S O'Leary; Robert I Block; Julie A Koeppel; Michael Flaum; Susan K Schultz; Nancy C Andreasen; Laura Boles Ponto; G Leonard Watkins; Richard R Hurtig; Richard D Hichwa
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

6.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

7.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

Review 8.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

9.  Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.

Authors:  Paolo Fusar-Poli; José A Crippa; Sagnik Bhattacharyya; Stefan J Borgwardt; Paul Allen; Rocio Martin-Santos; Marc Seal; Simon A Surguladze; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip K McGuire
Journal:  Arch Gen Psychiatry       Date:  2009-01

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  14 in total

1.  Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex.

Authors:  Chiayu Q Chiu; Nagore Puente; Pedro Grandes; Pablo E Castillo
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia.

Authors:  Johannes Rentzsch; Ada Stadtmann; Christiane Montag; Hagen Kunte; Doris Plöckl; Rainer Hellweg; Jürgen Gallinat; Golo Kronenberg; Maria Christiane Jockers-Scherübl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-17       Impact factor: 5.270

3.  Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Authors:  Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-08-29       Impact factor: 13.382

Review 4.  Drug targets: single-cell transcriptomics hastens unbiased discovery.

Authors:  Tamas Bartfai; Peter T Buckley; James Eberwine
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

5.  Startle reactivity and prepulse inhibition in prodromal and early psychosis: effects of age, antipsychotics, tobacco and cannabis in a vulnerable population.

Authors:  Kristin S Cadenhead
Journal:  Psychiatry Res       Date:  2011-05-08       Impact factor: 3.222

Review 6.  Drug models of schizophrenia.

Authors:  Hannah Steeds; Robin L Carhart-Harris; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

Review 7.  Substance use in clinical high risk for psychosis: a review of the literature.

Authors:  Jean Addington; Nevicia Case; Majid M Saleem; Andrea M Auther; Barbara A Cornblatt; Kristin S Cadenhead
Journal:  Early Interv Psychiatry       Date:  2013-11-14       Impact factor: 2.732

8.  CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation.

Authors:  Vincent Van Waes; Joel A Beverley; Homayoun Siman; Kuei Y Tseng; Heinz Steiner
Journal:  Front Pharmacol       Date:  2012-03-12       Impact factor: 5.810

9.  Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.

Authors:  Leonora E Long; Rose Chesworth; Xu-Feng Huang; Alexander Wong; Adena Spiro; Iain S McGregor; Jonathon C Arnold; Tim Karl
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

10.  Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain.

Authors:  Raquel Levin; Fernanda F Peres; Valéria Almeida; Mariana B Calzavara; Antonio W Zuardi; Jaime E C Hallak; José Alexandre S Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2014-02-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.